CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) insider Isabel Kalofonos bought 3,751 shares of the firm’s stock in a transaction that occurred on Wednesday, November 18th. The stock was acquired at an average cost of $79.75 per share, with a total value of $299,142.25. Following the transaction, the insider owned 3,751 shares of the company’s stock, valued at $299,142.25. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
CG Oncology Trading Up 1.3%
NASDAQ:CGON opened at $80.00 on Thursday. The stock has a market capitalization of $7.15 billion, a PE ratio of -28.99 and a beta of 0.35. CG Oncology, Inc. has a 1-year low of $37.01 and a 1-year high of $93.95. The firm has a fifty day simple moving average of $68.51 and a 200 day simple moving average of $66.96.
CG Oncology (NASDAQ:CGON – Get Free Report) last issued its earnings results on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. The company had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.55 million. On average, equities analysts predict that CG Oncology, Inc. will post -2.97 earnings per share for the current fiscal year.
More CG Oncology News
These are some of the CGON news items that stood out recently:
- Positive Sentiment: CEO Arthur Kuan bought 30,000 shares for about $2.37 million, increasing his direct holdings by 15.08%. Isabel Kalofonos also purchased 3,751 shares for roughly $299,000. These insider purchases may signal confidence in the company’s prospects. CEO SEC filing
- Positive Sentiment: Morgan Stanley raised its price target to $117 and maintained an Overweight rating. Truist and HC Wainwright also raised targets and reiterated Buy ratings, while Wedbush lifted its target and kept an Outperform rating. The analyst revisions reflect improved optimism following the trial news. Morgan Stanley rating
- Neutral Sentiment: Despite the favorable trial readout, investors may weigh the stock’s sharp rally and valuation against the still-developing clinical and regulatory outlook. Valuation discussion
Hedge Funds Weigh In On CG Oncology
Several institutional investors and hedge funds have recently modified their holdings of the business. Fiduciary Financial Advisors bought a new stake in CG Oncology in the 2nd quarter valued at about $28,000. Manchester Capital Management LLC grew its position in shares of CG Oncology by 2,895.5% during the 3rd quarter. Manchester Capital Management LLC now owns 659 shares of the company’s stock worth $47,000 after purchasing an additional 637 shares in the last quarter. Covestor Ltd grew its position in shares of CG Oncology by 72.6% during the 3rd quarter. Covestor Ltd now owns 770 shares of the company’s stock worth $55,000 after purchasing an additional 324 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of CG Oncology by 47.9% during the third quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock worth $77,000 after purchasing an additional 350 shares during the period. Finally, Fifth Third Bancorp bought a new position in shares of CG Oncology during the first quarter worth approximately $74,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the company. Morgan Stanley increased their price target on CG Oncology from $102.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday. Wedbush upped their price objective on shares of CG Oncology from $84.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Thursday, October 15th. Truist Financial reissued a “buy” rating and issued a $100.00 price objective (up from $85.00) on shares of CG Oncology in a research report on Tuesday. Finally, Royal Bank Of Canada cut shares of CG Oncology from an “outperform” rating to a “sector perform” rating and raised their target price for the stock from $80.00 to $97.00 in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, CG Oncology currently has an average rating of “Moderate Buy” and an average price target of $98.78.
Check Out Our Latest Report on CGON
CG Oncology Company Profile
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Featured Articles
- Five stocks we like better than CG Oncology
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
